Pharma Focus Asia
Klöckner Pentaplast - Pentapharm® alfoil® films

Enlivex Initiates Dosing of Initial Two Patients in Phase I/II Trial to Evaluate Allocetra™ for Knee Osteoarthritis

Tuesday, April 23, 2024

Enlivex Therapeutics Ltd. (Nasdaq: ENLV) has commenced dosing for the initial two patients in its Phase I/II trial evaluating AllocetraTM for moderate to severe knee osteoarthritis. This multi-country trial aims to enroll up to 160 patients.

The trial consists of two stages: an initial safety run-in phase and a subsequent randomized, controlled phase. The safety run-in phase, focusing on dose escalation and open-label administration, will determine the appropriate dosage and injection schedule for the randomized phase. Following the safety run-in, a double-blind, placebo-controlled stage will assess both safety and efficacy, with primary endpoints centered on joint-pain and joint-function compared to placebo at three, six, and twelve months post-treatment.

Dr. Einat Galamidi, Vice President of Medical at Enlivex, expressed satisfaction with the trial's progress, highlighting the enrollment and dosing of the initial participants. This phase is crucial in establishing the groundwork for the subsequent randomized stage.

Osteoarthritis, affecting millions worldwide, represents a significant unmet medical need, with current treatments primarily focused on symptom management. AllocetraTM, designed to reprogram macrophages into their normal state, offers a promising therapeutic approach for various diseases, including knee osteoarthritis, where macrophage dysfunction plays a significant role in disease severity.

This milestone marks a step forward in Enlivex's mission to address critical medical needs through innovative immunotherapy approaches.



magazine-slider-imageBIOVIA from Molecule to MedicineMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopCPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinRehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024